Urine Test May Detect Aggressive Prostate Cancer and Reduce Biopsies: Study
Researchers have developed a new home urine test, MyProstateScore 2.0, that has shown high sensitivity in detecting aggressive prostate cancer without requiring a digital rectal exam. The test could help men with lower risk avoid unnecessary biopsies and MRIs, offering a less invasive diagnostic option.
The 18-gene MyProstateScore 2.0 (MPS2) test was previously validated for detection of grade group ≥ 2 (GG ≥ 2) prostate cancer using post–digital rectal examination (DRE) urine. To improve ease of testing, we validated MPS2 using first-catch, non-DRE urine. Patients provided first-catch urine before biopsy. MPS2 values were calculated using previously validated models differing only by extent of clinical data included biomarkers alone (BA; no clinical data), biomarkers and clinical factors (BA + CF), and biomarkers, clinical factors, and prostate volume (BA + CF + PV). The primary outcome was GG ≥ 2 cancer on biopsy. MPS2 performance and clinical consequences of testing were compared with PSA and the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Results: The cohort included 266 men with median PSA 6.6 ng/mL (IQR, 4.9-9.1) of whom 103 (39%) had GG ≥ 2 cancer on biopsy. The AUC for GG ≥ 2 cancer was 57% for PSA, 62% for PCPTrc, and 71%, 74%, and 77% for MPS2 models. Under a testing approach detecting > 90% of GG ≥ 2 cancers, MPS2 testing would have avoided 36% to 42% of unnecessary biopsies, as compared with 13% using the PCPTrc. In patients with a prior negative biopsy, MPS2 testing would have avoided 44% to 53% of repeat biopsies, as compared with only 2.6% using PCPTrc. Using first-catch urine, MPS2 meaningfully improved the proportion of biopsies avoided relative to PCPTrc while maintaining highly sensitive detection of GG ≥ 2 cancer. Non-DRE testing provides a convenient, objective, and highly accurate testing option to reduce the need for imaging and biopsy in men with elevated PSA.
Reference:
Tosoian JJ, Zhang Y, Meyers JI, Heaton S, Siddiqui J, Xiao L, et al. Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non–Digital Rectal Examination Urine. Journal of Urology [Internet]. [cited 2025 Mar 13];0(0). Available from: https://www.auajournals.org/doi/abs/10.1097/JU.0000000000004421
Keywords:
Urine Test , Detect, Aggressive, Prostate Cancer, Reduce Biopsies, Study, Journal of Urology, Tosoian JJ, Zhang Y, Meyers JI, Heaton S, Siddiqui J, Xiao L
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.